Publications
Liver Safety of Statins in Prediabetes or T2DM and NASH
Abstract CONTEXT Patients with nonalcoholic fatty liver disease have a high cardiovascular risk, but statins are rarely prescribed because of fear of hepatotoxicity. OBJECTIVE To prospectively assess the long-term safety of statins in patients with prediabetes/type 2...
Liver and Cardiovascular Damage in Patients with NASH
Abstract BACKGROUND & AIMS Lean nonalcoholic fatty liver disease (NAFLD) is defined as NAFLD that develops in patients with a body mass index (BMI) less than 25 kg/m2. We investigated the differences between lean NAFLD and NAFLD in overweight and obese persons,...
Targeting Nuclear Receptors for the Treatment of Fatty Liver Disease
Abstract Ligand-activated nuclear receptors, including peroxisome proliferator-activated receptor alpha (PPARα), pregnane X receptor, and constitutive androstane receptor, were first identified as key regulators of the responses against chemical toxicants. However,...
Treatment of NAFLD with Diet, Physical Activity, and Exercise
Abstract Lifestyle intervention can be effective when treating non-alcoholic fatty liver diseases (NAFLD) patients. Weight loss decreases cardiovascular and diabetes risk and can also regress liver disease. Weight reductions of ⩾10% can induce a near universal...
What is NASH?
Do you have questions or are you looking for more information?
Resources
Keep informed with industry related news and publications.
About NASH Alliance
Learn more about our clinical advisory team of experts.